床旁钠尿肽检测在门诊慢性心衰中的诊断准确性:系统综述与荟萃分析
该系统综述与荟萃分析评估床旁钠尿肽检测在门诊慢性心衰患者中的诊断准确性,检索至2017年3月共纳入39项研究,其中37项进入分析。结果显示BNP在100 pg/mL阈值下灵敏度高(0.95),但门诊研究稀少、NTproBNP数据有限,需大规模初级保健试验明确适宜阈值。
要点
- 床旁BNP在100 pg/mL阈值下灵敏度为0.95,适合高危患者排除慢性心衰。
- 初级保健中NTproBNP在135 pg/mL阈值下灵敏度0.99、特异度0.60。
- 床旁BNP与NTproBNP的诊断准确性无统计学显著差异。
核心结论
- 床旁钠尿肽检测对慢性心衰具有较高诊断准确性,但门诊特别是初级保健研究不足,需大规模试验明确阈值。
研究设计与样本
- 系统综述与荟萃分析,检索8个数据库至2017年3月31日。
- 纳入39项研究,37项(40篇文献)进入分析;30项评估BNP,7项评估NTproBNP。
- 15项在门诊低患病率人群进行,仅5项在初级保健开展。
主要发现
- BNP床旁检测(Triage)在100 pg/mL阈值下灵敏度0.95(95%CI 0.90–0.98)。
- BNP在<100 pg/mL阈值下灵敏度0.46–0.97,特异度0.31–0.98。
- 初级保健NTproBNP在135 pg/mL阈值下灵敏度0.99(95%CI 0.57–1.00),特异度0.60(95%CI 0.44–0.74)。
- 床旁BNP与NTproBNP的诊断准确性无统计学显著差异。
临床怎么用
- 在门诊可考虑使用床旁BNP(100 pg/mL阈值)辅助排除慢性心衰。
- 初级保健使用NTproBNP(135 pg/mL阈值)时需注意特异度有限。
局限性
- 初级保健研究缺乏,NTproBNP数据稀少。
- 纳入研究存在潜在方法学局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the diagnostic accuracy of point-of-care natriuretic peptide tests in patients with chronic heart failure, with a focus on the ambulatory care setting. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Ovid Medline, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, Embase, Health Technology Assessment Database, Science Citation Index, and Conference Proceedings Citation Index until 31 March 2017. STUDY SELECTION: Eligible studies evaluated point-of-care natriuretic peptide testing (B-type natriuretic peptide (BNP) or N terminal fragment pro B-type natriuretic peptide (NTproBNP)) against any relevant reference standard, including echocardiography, clinical examination, or combinations of these, in humans. Studies were excluded if reported data were insufficient to construct 2×2 tables. No language restrictions were applied. RESULTS: 42 publications of 39 individual studies met the inclusion criteria and 40 publications of 37 studies were included in the analysis. Of the 37 studies, 30 evaluated BNP point-of-care testing and seven evaluated NTproBNP testing. 15 studies were done in ambulatory care settings in populations with a low prevalence of chronic heart failure. Five studies were done in primary care. At thresholds >100 pg/mL, the sensitivity of BNP, measured with the point-of-care index device Triage, was generally high and was 0.95 (95% confidence interval 0.90 to 0.98) at 100 pg/mL. At thresholds <100 pg/mL, sensitivity ranged from 0.46 to 0.97 and specificity from 0.31 to 0.98. Primary care studies that used NTproBNP testing reported a sensitivity of 0.99 (0.57 to 1.00) and specificity of 0.60 (0.44 to 0.74) at 135 pg/mL. No statistically significant difference in diagnostic accuracy was found between point-of-care BNP and NTproBNP tests. CONCLUSIONS: Given the lack of studies in primary care, the paucity of NTproBNP data, and potential methodological limitations in these studies, large scale trials in primary care are needed to assess the role of point-of-care natriuretic peptide testing and clarify appropriate thresholds to improve care of patients with suspected or chronic heart failure.
引用
- Taylor KS, Verbakel JY, Feakins BG, et al. Diagnostic accuracy of point-of-care natriuretic peptide testing for chronic heart failure in ambulatory care: systematic review and meta-analysis. BMJ. 2018. PMID: 29785952. doi:10.1136/bmj.k1450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。